Notice NOT-OD-21-040 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-064 from the NIH Guide for Grants and Contracts. The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting welldesigned and wellexecuted clinical trials. This funding opportunity announcement (FOA) supports a cooperative agreement between an NIDCD Project Scientist and an investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, has annual direct costs equal to or greater than $500,000, that is intended to formally establish efficacy, or has a higher risk to potentially cause physical or psychological harm. Clinical trial applications exceeding the annual direct costs of $700,000 or more may also be a criteria for this FOA. These investigator-initiated clinical trials are perceived to benefit from close interaction, oversight, and guidance resulting from a cooperative agreement. Only one clinical trial may be proposed in each NIDCD Clinical Trials in Communication Disorders U01 application.

Funding Opportunity PAR-21-063 from the NIH Guide for Grants and Contracts. The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials. This funding opportunity announcement (FOA) supports investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this FOA, not require FDA oversight, are not intended to formally establish efficacy and have low risks to potentially cause physical or psychological harm. This FOA also supports low risk trials determined to be Basic Science Experimental Studies involving Humans (BESH). These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. It is advisable that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application. High risk clinical trials not meeting all the criteria above are referred companion U01 FOA PAR-21-XXX, NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders.

The successful candidate will be knowledgeable in biological science concepts, particularly in molecular evolution, and have experience in the preparation of…
From University of Wisconsin–Madison - Fri, 11 Dec 2020 00:57:28 GMT - View all Madison, WI jobs

Funding Opportunity RFA-ES-21-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Phase I (R43) SBIR grant applications from small business concerns (SBCs) to develop promising methodologies using Artificial Intelligence (AI) and Machine Learning (ML) approaches to advance environmental health research and decisions. When developed and validated, these methodologies or approaches will further advance the accuracy of toxicity prediction, help in prioritizing chemicals for more relevant or targeted testing, identify and/or fill data or knowledge gaps in toxicity assessment, promote more comprehensive understanding of human exposures, susceptibility and adverse health outcomes.

Funding Opportunity RFA-ES-21-002 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Phase I (R43) SBIR grant applications from small business concerns (SBCs) to develop promising methodologies using Artificial Intelligence (AI) and Machine Learning (ML) approaches to advance environmental health research and decisions. When further developed and validated, these methodologies or approaches should improve the accuracy of toxicity prediction, help in prioritizing chemicals for more relevant or targeted testing, identify and/or fill data or knowledge gaps in toxicity assessment, and promote more comprehensive understanding of human exposure effects, susceptibility and adverse health outcomes.

Competitive Salary: F. Hoffmann-La Roche AG: At Roche we believe it’s urgent to deliver medical solutions right now – even as we develop innovations for the future. We are passionate about trans Switzerland (CH)

Notice NOT-LM-21-003 from the NIH Guide for Grants and Contracts

Notice NOT-GM-21-005 from the NIH Guide for Grants and Contracts

Notice NOT-HG-21-020 from the NIH Guide for Grants and Contracts

£46,000 to £52,000 dependent on experience: Wellcome Sanger Institute:  We are seeking to recruit a Principal Bioinformatician who can push the boundaries of one of the world’s key cancer genomics resources. Hinxton, Cambridgeshire

Funding Opportunity RFA-TR-21-001 from the NIH Guide for Grants and Contracts. The purpose of the ASPIRE Collaborative Research Program is to facilitate translational and clinical research between NCATS intramural scientists and the extramural community to develop approaches that will enhance the ability to discover and develop new chemistries towards previously undrugged biological targets (i.e., biological targets with no known drugs to modulate their function) across many human diseases and conditions. NCATS intramural scientists have established an integrated NCATS ASPIRE platform consisting of physical and virtual modules for automated synthetic chemistry, artificial intelligence (AI) and machine learning (ML), engineering, informatics, and biological testing. The FOA will support intramural - extramural collaborations to develop additional physical modules that will enhance the platforms capabilities. The anticipated outcome includes identification, design, synthesis, and validation of new chemical entities as starting points for drug development of novel targets, and the expansion of chemical space available for drug screening.

Funding Opportunity RFA-TR-21-002 from the NIH Guide for Grants and Contracts. The purpose of the ASPIRE Collaborative Research Program is to facilitate translational and clinical research between NCATS intramural scientists and the extramural community to develop approaches that will enhance our ability to discover and develop new chemistries designed towards previously undrugged biological targets (i.e., biological targets with no known drugs to modulate their function) across many human diseases and conditions. NCATS intramural scientists have established an integrated platform consisting of physical and virtual modules for automated synthetic chemistry, artificial intelligence (AI) and machine learning (ML), engineering, informatics, and biological testing. This FOA will support intramural - extramural collaborations to develop virtual modules that will enhance the platforms capabilities (see companion RFA-TR-21-001 for physical modules). The anticipated outcome includes identification, design, synthesis, and validation of new chemical entities as starting points for drug development of novel targets, and the expansion of chemical space available for drug screening.

Funding Opportunity RFA-AG-22-002 from the NIH Guide for Grants and Contracts. This FOA seeks to support studies on normal and pathobiological changes in aging bone marrow that impact, or are impacted by, changes in immune function with age. Studies to be supported are in the field of osteoimmunology, which concerns the bidirectional interactions between bone and the immune system. The importance of osteoimmunology and its potential for improving the understanding of bone homeostasis is now recognized. However, most research has been conducted in young mice (3-4 months) that have not completed growth and development. Young animals cannot exhibit the relevant age-associated changes in immune function in the marrow niche that can best be revealed by comparison of older mice (at or older than 18 months) to young adult mice (at least 4 months of age). While important insights have been gained about osteoimmunological signaling pathways in the bone marrow niche of young adults, this approach has not addressed important questions more directly focused on age-related bone loss and the myriad of complex tissue interactions one expects, since bone is an endocrine organ. Pathobiological changes that occur in the aging marrow niche, such as myeloid skewing and declining immune function, are well-documented in the field of immunology. In addition, the role of T cells in osteoclast differentiation, bone resorption, and bone turnover have been demonstrated. However, many questions remain regarding how and why these changes occur over time in both healthy adults and older adults where bone loss is more commonly a major concern. The effect of age on healthy (adaptive) and pathobiological (maladaptive) changes that occur in the aging marrow niche and how these changes affect health trajectories in age-appropriate laboratory animals are the focus of this FOA.

Notice NOT-DK-21-008 from the NIH Guide for Grants and Contracts

Notice NOT-DK-21-010 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MH-21-117 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to support studies to better understand the underlying mechanisms and interplay of biological, psychosocial and structural factors contributing to mood disorders in people living with HIV. Exploratory and high-risk research projects are appro?priate for this funding opportunity announcement. Applications testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data should consider applying to the companion R01 announcement RFA-MH-21-116. Basic and preclinical research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Funding Opportunity RFA-MH-21-116 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to support studies to better understand the underlying mechanisms and interplay of biological, psychosocial and structural factors contributing to mood disorders in people living with HIV. Applications testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data are appropriate for this funding opportunity announcement. Exploratory and high-risk research projects should c?onsider applying to the companion R21 announcement RFA-MH-21-117. Basic and preclinical research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Funding Opportunity RFA-CA-21-002 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for Cellular Cancer Biology Imaging Research (CCBIR) Centers. The Centers will develop and test enabling imaging technologies at the cellular and organ scales driven by specific fundamental questions in cancer biology. The overall purpose of the CCBIR initiative is to facilitate innovation in advanced imaging technologies that could be applied to fundamental basic and pre-clinical research problems in cancer biology. CCBIR Centers are structured to operate collaboratively between technology developers and cancer biologists at the forefront of their respective fields. CCBIR Centers will increase in experimental sophistication over time to ultimately produce an interoperable suite of state-of-the-art imaging technologies with transformative potential to study the cancer biology process(es) that defines the Center. The cadre of CCBIR Centers will form a consortium that will be expected to engage with the broader cancer research community.

Notice NOT-OD-21-037 from the NIH Guide for Grants and Contracts